Chinese life sciences firm Wuxi Biologics has increased the value of its investment in its Worcester facility from the original $60 million to now $300 million.

WuXi held a topping off ceremony for the new facility on Sept. 27, as it reached the completion of the steel erection of its new commercial biomanufacturing facility, scheduled to open in 2024. With the increased investment, the originally planned 107,000-square-foot clinical biomanufacturing suite announced in 2019 will now be a 189,500-square-foot facility. The WuXi Worcester facility inside The Reactory biomanufacturing campus will employ 250 workers.

WuXi is a global contract research, development and manufacturing organization that partners with other companies to help them produce and manufacture products. Plans for what kinds of products will be made at the new facility have not been announced yet.